 |
JOURNAL TOOLS |
| Publishing options |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Reprints |
| Permissions |
| Share |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
ENDOCRINE ONCOLOGY
Minerva Endocrinologica 2012 June;37(2):117-32
Copyright © 2012 EDIZIONI MINERVA MEDICA
language: English
Endometrial carcinoma tumorigenesis and pharmacotherapy research
Shu J. 1, Fang S. 2, Teichman P. G. 3, Xing L. 1, Huang H. 4 ✉
1 School of Medicine, Zhejiang University, Hangzhou, China; 2 Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China; 3 Genesys Regional Medical Center, Michigan State University, Grand Blanc, MI, USA; 4 Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Endometrial carcinoma is the common malignant tumor of the female genital tract, and its incidence is increasing. Two different clinicopathological subtypes are recognized based on epidemiology, genetic carcinogenesis and clinical behavior. Understanding and identifying molecular biology and genetics is essential to the development of novel therapies. This article reviews the current understanding of its risk factors, recent conceptions on its tumorigenesis and advances on its drug therapies.